These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 17047914)
1. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Distiller LA; Joffe BI Diabetologia; 2006 Nov; 49(11):2793-4. PubMed ID: 17047914 [No Abstract] [Full Text] [Related]
2. Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 49:2793-2794. Bell DS Diabetologia; 2007 Mar; 50(3):695. PubMed ID: 17235522 [No Abstract] [Full Text] [Related]
3. Optimizing glycemic control with insulin glargine. Williams JB Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834 [No Abstract] [Full Text] [Related]
4. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161 [TBL] [Abstract][Full Text] [Related]
5. Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec. Takahashi N; Tsujimoto T; Inoue K; Kishimoto M; Kajio H J Diabetes Investig; 2016 Sep; 7(5):805-6. PubMed ID: 27586093 [TBL] [Abstract][Full Text] [Related]
6. [Flexible intensive insulin therapy: a change in mentalities]. Penfornis A; Chabroux S; Grimaldi A Rev Med Interne; 2008 Nov; 29(11):857-60. PubMed ID: 18387717 [No Abstract] [Full Text] [Related]
7. Will the use of insulin analogs improve glycemic control during adolescence? Dunger DB Pediatr Diabetes; 2003 Jun; 4(2):61-3. PubMed ID: 14655260 [No Abstract] [Full Text] [Related]
8. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K; Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478 [No Abstract] [Full Text] [Related]
9. Effects of mixing glargine and short-acting insulin analogs on glucose control. Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016 [No Abstract] [Full Text] [Related]
10. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118 [TBL] [Abstract][Full Text] [Related]
11. An update on the long-acting insulin analogue glargine. Thisted H; Johnsen SP; Rungby J Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163 [TBL] [Abstract][Full Text] [Related]
12. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Päivärinta M; Tapanainen P; Veijola R Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431 [TBL] [Abstract][Full Text] [Related]
13. Fasting and insulin glargine in individuals with type 1 diabetes. Mucha GT; Merkel S; Thomas W; Bantle JP Diabetes Care; 2004 May; 27(5):1209-10. PubMed ID: 15111549 [No Abstract] [Full Text] [Related]
14. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471 [TBL] [Abstract][Full Text] [Related]
15. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456 [TBL] [Abstract][Full Text] [Related]
16. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953 [No Abstract] [Full Text] [Related]
17. Insulin glargine: a new basal insulin analogue. Younis N; Soran H; Bowen-Jones D QJM; 2002 Nov; 95(11):757-61. PubMed ID: 12391389 [No Abstract] [Full Text] [Related]
18. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes. Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408 [TBL] [Abstract][Full Text] [Related]
19. [A study of variability in glycaemia in children and adolescents with diabetes mellitus type 1 on treatment with insulin glargine]. Rodríguez Pérez C; Lizondo Escuder A; López García MJ; Escrivá Cholbi L; Alpera Lacruz R; Collado Pérez C An Pediatr (Barc); 2008 Nov; 69(5):426-31. PubMed ID: 19128743 [TBL] [Abstract][Full Text] [Related]
20. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients. Gallen IW; Carter C Diabetes Care; 2003 Dec; 26(12):3352-3. PubMed ID: 14633830 [No Abstract] [Full Text] [Related] [Next] [New Search]